These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
176 related articles for article (PubMed ID: 38184393)
1. Long-term surveillance of invasive pneumococcal disease: The impact of 10-valent pneumococcal conjugate vaccine in the metropolitan region of Salvador, Brazil. Reis JN; Azevedo J; de Oliveira AML; Menezes APO; Pedrosa M; Dos Santos MS; Ribeiro LC; Freitas HF; Gouveia EL; Teles MB; Carvalho MDG; Reis MG; Nascimento-Carvalho C; Verani JR Vaccine; 2024 Jan; 42(3):591-597. PubMed ID: 38184393 [TBL] [Abstract][Full Text] [Related]
2. Distribution of invasive Streptococcus pneumoniae serotypes before and 5 years after the introduction of 10-valent pneumococcal conjugate vaccine in Brazil. Brandileone MC; Almeida SCG; Minamisava R; Andrade AL Vaccine; 2018 May; 36(19):2559-2566. PubMed ID: 29650385 [TBL] [Abstract][Full Text] [Related]
3. Long-term population impact of infant 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease in adults in Finland. Nuorti JP; Rinta-Kokko H; Toropainen M; Siira L; Nohynek H; Palmu AA Vaccine; 2022 Sep; 40(41):5950-5958. PubMed ID: 36075797 [TBL] [Abstract][Full Text] [Related]
4. Long-term impact of 10-valent pneumococcal conjugate vaccination on invasive pneumococcal disease among children in Finland. Rinta-Kokko H; Palmu AA; Auranen K; Nuorti JP; Toropainen M; Siira L; Virtanen MJ; Nohynek H; Jokinen J Vaccine; 2018 Apr; 36(15):1934-1940. PubMed ID: 29526371 [TBL] [Abstract][Full Text] [Related]
5. Long-term Impact of a "3 + 0" Schedule for 7- and 13-Valent Pneumococcal Conjugate Vaccines on Invasive Pneumococcal Disease in Australia, 2002-2014. Jayasinghe S; Menzies R; Chiu C; Toms C; Blyth CC; Krause V; McIntyre P Clin Infect Dis; 2017 Jan; 64(2):175-183. PubMed ID: 27986682 [TBL] [Abstract][Full Text] [Related]
6. Impact and effectiveness of the 10-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children under 5 years of age in the Netherlands. Peckeu L; van der Ende A; de Melker HE; Sanders EAM; Knol MJ Vaccine; 2021 Jan; 39(2):431-437. PubMed ID: 33243632 [TBL] [Abstract][Full Text] [Related]
7. Effect of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease and nasopharyngeal carriage in Kenya: a longitudinal surveillance study. Hammitt LL; Etyang AO; Morpeth SC; Ojal J; Mutuku A; Mturi N; Moisi JC; Adetifa IM; Karani A; Akech DO; Otiende M; Bwanaali T; Wafula J; Mataza C; Mumbo E; Tabu C; Knoll MD; Bauni E; Marsh K; Williams TN; Kamau T; Sharif SK; Levine OS; Scott JAG Lancet; 2019 May; 393(10186):2146-2154. PubMed ID: 31000194 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of 10 and 13-valent pneumococcal conjugate vaccines against invasive pneumococcal disease in European children: SpIDnet observational multicentre study. Savulescu C; Krizova P; Valentiner-Branth P; Ladhani S; Rinta-Kokko H; Levy C; Mereckiene J; Knol M; Winje BA; Ciruela P; de Miguel S; Guevara M; MacDonald L; Kozakova J; Slotved HC; Fry NK; Pekka Nuorti J; Danis K; Corcoran M; van der Ende A; Vestrheim DF; Munoz-Almagro C; Sanz JC; Castilla J; Smith A; Colzani E; Pastore Celentano L; Hanquet G; Vaccine; 2022 Jun; 40(29):3963-3974. PubMed ID: 35637067 [TBL] [Abstract][Full Text] [Related]
9. Invasive pneumococcal diseases in children and adults before and after introduction of the 10-valent pneumococcal conjugate vaccine into the Austrian national immunization program. Richter L; Schmid D; Kanitz EE; Zwazl I; Pöllabauer E; Jasinska J; Burgmann H; Kundi M; Wiedermann U PLoS One; 2019; 14(1):e0210081. PubMed ID: 30629620 [TBL] [Abstract][Full Text] [Related]
10. Effectiveness of ten-valent pneumococcal conjugate vaccine against invasive pneumococcal disease in Brazil: a matched case-control study. Domingues CM; Verani JR; Montenegro Renoiner EI; de Cunto Brandileone MC; Flannery B; de Oliveira LH; Santos JB; de Moraes JC; Lancet Respir Med; 2014 Jun; 2(6):464-71. PubMed ID: 24726406 [TBL] [Abstract][Full Text] [Related]
11. Invasive disease potential of Streptococcus pneumoniae serotypes before and after 10-valent pneumococcal conjugate vaccine introduction in a rural area, southern Mozambique. Massora S; Lessa FC; Moiane B; Pimenta FC; Mucavele H; Chaúque A; Cossa A; Verani JR; Tembe N; da Gloria Carvalho M; Muñoz-Almagro C; Sigaúque B Vaccine; 2019 Dec; 37(51):7470-7477. PubMed ID: 31575493 [TBL] [Abstract][Full Text] [Related]
12. Effectiveness of ten-valent pneumococcal conjugate vaccine on invasive pneumococcal disease among children <2 years old: A prospective population-based study in rural Bangladesh. Malaker R; Hasanuzzaman M; Hooda Y; Rahman H; Chandra Das R; Kanon N; Saha S; Tanmoy AM; Ranjan Chakraborty S; Saha S; Islam M; Darmstadt GL; Baqui AH; Sathosam M; El-Arifeen S; Whitney CG; Saha SK Vaccine; 2024 Jan; 42(2):255-262. PubMed ID: 38071104 [TBL] [Abstract][Full Text] [Related]
13. Invasive pneumococcal disease in Canada 2010-2017: The role of current and next-generation higher-valent pneumococcal conjugate vaccines. Dion SB; Major M; Gabriela Grajales A; Nepal RM; Cane A; Gessner B; Vojicic J; Suaya JA Vaccine; 2021 May; 39(22):3007-3017. PubMed ID: 33824041 [TBL] [Abstract][Full Text] [Related]
14. Invasive pneumococcal disease 3 years after introduction of a reduced 1 + 1 infant 13-valent pneumococcal conjugate vaccine immunisation schedule in England: a prospective national observational surveillance study. Bertran M; D'Aeth JC; Abdullahi F; Eletu S; Andrews NJ; Ramsay ME; Litt DJ; Ladhani SN Lancet Infect Dis; 2024 May; 24(5):546-556. PubMed ID: 38310905 [TBL] [Abstract][Full Text] [Related]
15. Dynamics of Invasive Pneumococcal Disease in Israel in Children and Adults in the 13-Valent Pneumococcal Conjugate Vaccine (PCV13) Era: A Nationwide Prospective Surveillance. Ben-Shimol S; Regev-Yochay G; Givon-Lavi N; van der Beek BA; Brosh-Nissimov T; Peretz A; Megged O; Dagan R; ; Clin Infect Dis; 2022 May; 74(9):1639-1649. PubMed ID: 34293091 [TBL] [Abstract][Full Text] [Related]
16. Serotype distribution of Streptococcus pneumoniae causing invasive disease in children in the post-PCV era: A systematic review and meta-analysis. Balsells E; Guillot L; Nair H; Kyaw MH PLoS One; 2017; 12(5):e0177113. PubMed ID: 28486544 [TBL] [Abstract][Full Text] [Related]
17. Dynamic changes in paediatric invasive pneumococcal disease after sequential switches of conjugate vaccine in Belgium: a national retrospective observational study. Desmet S; Lagrou K; Wyndham-Thomas C; Braeye T; Verhaegen J; Maes P; Fieuws S; Peetermans WE; Blumental S Lancet Infect Dis; 2021 Jan; 21(1):127-136. PubMed ID: 32702303 [TBL] [Abstract][Full Text] [Related]
18. Invasive pneumococcal disease among the elderly in the later era of paediatric pneumococcal conjugate vaccination-A longitudinal study over 10 years based on public surveillance data in the Nordics. Palmborg A; Skovdal M; Molden T; Åhman H; Chen L; Banefelt J PLoS One; 2023; 18(6):e0287378. PubMed ID: 37363884 [TBL] [Abstract][Full Text] [Related]
19. Distribution of serotypes causing invasive pneumococcal disease in older adults from high-income countries and impact of pediatric and adult vaccination policies. Grant LR; Slack MPE; Theilacker C; Vojicic J; Dion S; Reinert RR; Jodar L; Gessner BD Vaccine; 2023 Aug; 41(38):5662-5669. PubMed ID: 37544825 [TBL] [Abstract][Full Text] [Related]
20. Pneumococcal serotype evolution in Western Europe. Tin Tin Htar M; Christopoulou D; Schmitt HJ BMC Infect Dis; 2015 Oct; 15():419. PubMed ID: 26468008 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]